Features June 2010 Issue

Fenofibrates Get a Second Look

Research shows popular drugs fail to lower cardiovascular risk for most patients already taking a statin.

The findings of the large Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, published online in New England Journal of Medicine on March 14, 2010, are giving physicians cause to rethink how some lipid abnormalities are treated. The trial found that combination therapy with fenofibric acid and statins was no better than statins alone at reducing cardiovascular risk in patients with diabetes.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.